EP Patent

EP1005863A1 — Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof

Assigned to Sanofi Aventis France · Expires 2000-06-07 · 26y expired

What this patent protects

The present invention relates to controlled-release dosage forms of short acting hypnotics or salts thereof adapted to release the short acting hypnotic over a predetermined time period, according to a biphasic profile of dissolution, where the first phase is an immediate release…

USPTO Abstract

The present invention relates to controlled-release dosage forms of short acting hypnotics or salts thereof adapted to release the short acting hypnotic over a predetermined time period, according to a biphasic profile of dissolution, where the first phase is an immediate release phase and the second phase is a prolonged release phase.

Drugs covered by this patent

Patent Metadata

Patent number
EP1005863A1
Jurisdiction
EP
Classification
—
Expires
2000-06-07
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi Aventis France
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.